SCHEMBL3788099

SCHEMBL3788099

CC(C)(C)n1nc(CO)c2c(N)ncnc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 15/20 0.57
ABL1 P00519 10/20 0.57
RIPK2 O43353 4/20 0.57
FYN P06241 4/20 0.57
PRKACA P17612 3/20 0.57
CSNK1A1 P48729 3/20 0.57
MAPK14 Q16539 3/20 0.57
PRKD3 O94806 3/20 0.57
CSK P41240 3/20 0.57
PRKD2 Q9BZL6 3/20 0.57
MAPK8 P45983 3/20 0.57
CDK2 P24941 2/20 0.57
PRKD1 Q15139 2/20 0.57
CAMK2A Q9UQM7 2/20 0.57
CSNK1E P49674 1/20 0.57
CDK12 Q9NYV4 1/20 0.57
AKT1 P31749 1/20 0.57
KDR P35968 4/20 0.53
RET P07949 4/20 0.53
EGFR P00533 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3788404 0.80 SRC (0.57) SRCABL1RIPK2FYNPRKACA
SCHEMBL409554 0.80 SRC (0.65) SRCABL1RIPK2FYNPRKACA
SCHEMBL3782929 0.80 SRC (0.58) SRCABL1RIPK2FYNPRKACA
SCHEMBL3785884 0.79 SRC (0.74) SRCABL1RIPK2FYNPRKACA
SCHEMBL12551769 0.79 SRC (0.64) SRCABL1RIPK2FYNPRKACA
SCHEMBL13019650 0.79 SRC (0.64) SRCABL1RIPK2FYNPRKACA
SCHEMBL24353313 0.79 SRC (0.49) SRCABL1RIPK2FYNPRKACA
SCHEMBL1962110 0.78 SRC (0.66) SRCABL1RIPK2FYNPRKACA
SCHEMBL13063872 0.78 SRC (0.66) SRCABL1RIPK2FYNPRKACA
SCHEMBL1965431 0.78 SRC (0.51) SRCABL1RIPK2FYNPRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2010-12-30 US disclosed
WO-2009062118-A2 MODULATION OF PROTEIN TRAFFICKING FOLDRX PHARMACEUTICALS, INC. (US) 2009-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331297-A1 MODULATION OF PROTEIN TRAFFICKING RAB1A, COPB1, GOLT1B SRC 1332/4885ABL1 1725/4885RIPK2 2849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.